CardioGen-82 infusion system produces rubidium Rb 82 chloride injection for intravenous administration. Source: skeeze / Pixabay.

Bracco Diagnostics, the US subsidiary of Italy-based Bracco Imaging, has launched the CardioGen-82 infusion system after receiving approval from the Food and Drug Administration (FDA).

CardioGen-82 infusion system is designed to improve automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The infusion system model will replace the company’s current infusion system.

The closed system produces rubidium Rb 82 chloride injection for intravenous administration.

Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for the PET imaging of the myocardium under rest or pharmacologic stress conditions.

It assesses regional myocardial perfusion in adult patients suspected of having coronary artery disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bracco Diagnostics president and CEO Vittorio Puppo said: “The new infusion system exemplifies Bracco’s significant investment in the cardiac PET imaging modality and is the culmination of thoughtful design and feedback from healthcare providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve.”

The company said that the new system has better intuitive and ergonomic details that offer easy access to all system components while reducing the radiation exposure for staff and patients.

It provides dosing options and other protocol parameters, which enables clinicians to make changes in scheduling and accommodate patient needs easily.

Last year, Bracco Imaging signed a definitive agreement to acquire all outstanding shares of UK molecular imaging company Blue Earth Diagnostics in a deal valued at $450m.

In 2016, the FDA granted approval for Bracco Diagnostics’ Lumason for ultrasonography of the liver.